Skip to content

Application of laser confocal microendoscopy in the diagnosis of prostate cancer

Application of laser confocal microendoscopy in the diagnosis of prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070808
Enrollment
Unknown
Registered
2023-04-24
Start date
2023-04-24
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Index test:Confocal microendoscopy

Sponsors

The Second Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Prostate MRI PIRADS score above 3 points; 2) Patients undergoing prostate biopsy; 3) Patients with prostate cancer whose clinical information can be collected, including age, previous medical history, time of diagnosis, clinical stage, pathological type, and treatment history 4) Age 50-80 years old 5) Patients who voluntarily accept the treatment arranged by the researcher and sign the informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with no abnormal prostate MRI 2) Patients who do not accept or cannot cooperate with prostate biopsy 3) Prostate cancer patients who did not sign informed consent

Design outcomes

Primary

MeasureTime frame
To explore the feasibility of laser confocal microendoscopy for in vitro diagnosis of prostate puncture, that is, its consistency with pathological diagnosis;

Secondary

MeasureTime frame
Area Under Curve, AUC;Sensitivity,SEN;Specificity,SPE;Incidence rate of adverse events and serious adverse events;positive predictive value ,PPV;negative predictive value,NPV;

Countries

China

Contacts

Public ContactZhiyu Liu

The Second Affiliated Hospital of Dalian Medical University

letter89@163.com+86 17709870009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026